Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Prostatic Neoplasms 1Obesity 1Metabolic Syndrome 1Melanoma 1Inflammation 1Dyslipidemias 1

Interventions

pembrolizumab 16Nivolumab 15Ipilimumab 12cemiplimab 10aldesleukin 6Interleukin-2 6Cyclophosphamide 6fludarabine 5fludarabine phosphate 4encorafenib 4binimetinib 4Blood Specimen Collection 4avelumab 3Sirolimus 3trametinib 2spartalizumab 2lifileucel 2dabrafenib 2atezolizumab 2Vemurafenib 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Prednisone 2Niacinamide 2Exercise 2Everolimus 2Dermoscopy 2Biopsy 2urelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Naltrexone × 1 year × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡